New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Subscribe To Our Newsletter & Stay Updated
